Please check the following:
- {{x.value}}
FREE membership
FREE membership
Join Intelligent Investor today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
Log in
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Congratulations!
You now have free access to InvestSMART, we look forward to helping you on your financial journey.
You now have access to Free Eureka Report Insights, We look forward to helping you on your financial journey.
You now have access to Intelligent Investor Free Insights. We look forward to helping you build a market beating stock portfolio.
Looking for more…
Intelligent Investor Membership
15-day Free Trial
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
No thanks
Looking for more…
Eureka Report Membership
15-day Free Trial
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
No thanks
Opthea Limited (ASX: OPT) - Share Price and Research
- Current share price for OPT : $0.675
Opthea Limited (OPT), an ASX-listed company, develops and commercialize therapies primarily for eye disease. Opthea's lead asset, sozinibercept (OPT-302), is a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3" in clinical development as a novel therapy for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Wet AMD and DME are leading causes of blindness in the elderly and diabetic populations respectively and are increasing in prevalence worldwide.
OPT General Information +
| ASX Code | OPT |
| Website | http://www.opthea.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 447 |
| OPT Share Price | $0.675 |
| Day High | $0.720 |
| Day Low | $0.665 |
| Last Close | $0.675 |
| OPT Share Price Movement | - ( No change ) |
Prices as at 16:40, 23 Apr 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
OPT Related Research
Opthea Limited (OPT) Upcoming Dividends & Yields
There are no dividends for Opthea Limited (OPT). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Opthea Limited (OPT) Recent ASX Announcements
| Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
|---|---|---|---|---|---|
| Notification regarding unquoted securities - OPT | 15 Apr 2024 11:19AM | $0.700 | $0.675 | $0.660 | fallen by 3.57% |
| Notification regarding unquoted securities - OPT | 15 Apr 2024 10:54AM | $0.695 | $0.675 | $0.660 | fallen by 2.88% |
| Opthea Appoints John Han, PharmD, as VP Medical Affairs | 9 Apr 2024 8:23AM | $0.745 | $0.675 | $0.660 | fallen by 9.40% |
- + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.
See all ASX announcements from Opthea Limited (OPT) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
OPT Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025F | C2 | -$5.00 | -13.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024F | C2 | -$5.80 | -87.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$214.96 | -$45.80 | 26.70% | 0.00 | 0.00 | 0.00% | 0.0% |
OPT Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | ||
| CSL (CSL) | $133,122M | -0.0712 | 0.1072 | 0.1864 | 40.3170 | 36.4137 | 30.6930 | 1.29% | 1.22% | 1.37% |
| Clinuvel Pharmaceuticals (CUV) | $714M | 0.4665 | 0.2049 | 0.1566 | 24.1117 | 20.0112 | 17.3021 | 0.35% | 0.49% | 0.56% |
| Mesoblast (MSB) | $908M | -0.1037 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Opthea (OPT) | $431M | 0.2671 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals (TLX) | $4,659M | -1.3767 | 0.0000 | 0.0000 | 111.7274 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
OPT Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | -37.90 | 0.00 |
| Market | 0.40 | 15.10 | 1.10 | 1.04 |
| Sector | 1.35 | 21.50 | 1.92 | 0.97 |
OPT Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Jeremy Levin | Non-Executive Chairman, Non-Executive Director | 12 Oct 2020 |
| Mr Lawrence Bernard Gozlan | Non-Executive Director | 24 Jul 2020 |
| Dr Julia Haller | Non-Executive Director | 1 Jun 2021 |
| Dr Susan Orr | Non-Executive Director | 21 Apr 2022 |
| Mr Quinton Oswald | Non-Executive Director | 21 Apr 2022 |
| Mr Anshul Thakral | Non-Executive Director | 7 Jun 2023 |
| Mr Sujal Arun Shah | Non-Executive Director | 4 Apr 2024 |
Opthea Limited (OPT) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 1 Mar 2024 | BALDWIN, Megan | Sell | Indirect Shares | 3,012,277 | $0.550 | $1,656,752.350 |
| 1 Mar 2024 | BALDWIN, Megan | Sell | Direct Shares | 987,723 | $0.550 | $543,247.650 |
| 28 Nov 2022 | BALDWIN, Megan | Buy | Indirect Shares | 355,901 | $0.480 | $170,832.480 |
See all changes in directors' interest & trades for Opthea Limited (OPT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
OPT Management
| Name | Position |
|---|---|
| Judith Robertson | Chief Commercial Officer |
| Frederic Guerard | Chief Executive Officer |
| Timothy Morris | Chief Financial Officer |
| Joel Naor | Chief Medical Officer |
| Karen Adams | Company Secretary,Vice President of Finance |
OPT Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Opthea Limited (OPT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 93,246,599 (20%) | Regal Funds Management Pty Limited |
| 33,322,088 (7.10%) | USB Group AG |
| 31,627,844 (6.80%) | Bakers Brothers Life Sciences LP |
| 23,425,608 (5%) | Bank of America Corporation and its related bodies corporate |
OPT Calendar of Events
| Date | Event |
|---|---|
| 27 February 2025 | Report (Interim) |
| 26 September 2024 | Report (Annual) |
| 29 August 2024 | Report (Prelim) |
FAQs about Opthea Limited (OPT)
What is the current share price of Opthea Limited (OPT)?
Opthea Limited's (OPT) current share price is $0.68. This constitutes a price movement of 2.27% when compared to the share price 7 days ago and is -10% below OPT's 12-month high of $0.75 per share. Prices are delayed by at least 20 minutes.
What is the share price movement for Opthea Limited (OPT)?
Relative to the previous close share price of $0.68, Opthea Limited's (OPT) current share price of $0.68 constitutes a movement of or 0%. Opthea Limited's (OPT) share price movement is 2.27% when compared to 7 days ago and is -10% below OPT's 52-week high of $0.75.
What is the 52-week high share price for Opthea Limited (OPT)?
Opthea Limited's (OPT) 52-week high is $0.75 which was reached on 2 Apr 2024. Relative to this, OPT's current share price of $0.68 constitutes a -$0.08 or -10% drop since that high of $0.75 per OPT share.
What is the 52-week low share price for Opthea Limited (OPT)?
Opthea Limited's (OPT) 52-week low is $0.32 which was reached on 2 Oct 2023. Relative to this, OPT's current share price of $0.68 constitutes a $0.36 or 114.29% gain since that low of $0.32 per OPT share.
What is the daily average trading volume for Opthea Limited (OPT)?
Over the last 12 months, Opthea Limited (OPT) has a daily average trading volume of 432,421 OPT shares per day.
What is the dividend yield for Opthea Limited (OPT)?
Opthea Limited (OPT) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for OPT is a ratio that tells you the percentage of Opthea Limited's (OPT) share price that it pays out in dividends each year.
What is the franking level for Opthea Limited (OPT)?
Opthea Limited (OPT) has a franking level of 0%. Franking represents the tax Opthea Limited (OPT) has already paid on any profit it distributes to shareholders as a dividend.
When does Opthea Limited (OPT) release its next Annual Report?
Opthea Limited (OPT) will release its next Annual Report on 26 September 2024. Opthea Limited's (OPT) last annual report was released on 28 Sep 2023. Click here to view Opthea Limited's (OPT) last annual report.
In which sector is Opthea Limited (OPT) classified?
Opthea Limited (OPT) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Cochlear Limited (COH), and Fisher & Paykel Healthcare Corporation Limited (FPH).
What is the price-to-earnings (P/E) ratio for Opthea Limited (OPT)?
The price-to-earnings (P/E) ratio for Opthea Limited (OPT) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Opthea Limited's (OPT) share price to its earnings per OPT share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
